 Cancer therapeutics biotech Immutep ASX:IMM has enrolled and dosed the last patient for a segment of its phase 2 study into cancer treatments. The recruitment and dosing milestone was for stage 2 of Part A of its TACTI-002 phase II study. The study is being conducted with Merck in the US to check how well ... 